A pair of artificial intelligence algorithms from Boston Scientific and Medtronic can ... a toolkit dedicated to providing at-home monitoring for people living with heart failure.

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Boston Scientific will purchase Ajax Health's Cortex and its OptiMap system to guide physicians performing AFib-treating ...

monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Boston Scientific options trades with real-time alerts from Benzinga Pro.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Background: Patients over the age of 75 represent more than half the recipients of permanent pacemakers. It is not known if they have a different risk of complications than younger patients.

Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported basis and 15% on an organic basis, compared to prior guidance of 13.5%-14.5% and 13%-14% ...

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...